Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?

被引：0
作者：
Han, B. [1 ]
Zhang, B. [1 ]
Xu, J. [1 ]
Zhang, Y. [1 ]
Zhang, X. [1 ]
Chu, T. [1 ]
Wang, S. [1 ]
Qiao, R. [1 ]
Qian, J. [1 ]
Lu, J. [1 ]
Zhang, L. [1 ]
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK; ros1; crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-29
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [21] A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
    Lixia Ju
    Mingquan Han
    Jinmei Su
    Chunyan Wu
    Zhengwei Dong
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 561 - 564
  • [22] CLINICAL ACTIVITY OF CRIZOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING THE ROS1 GENE REARRANGEMENT
    Ou, Sai-hong I.
    Bang, Y-j
    Camidge, D. R.
    Engelman, J. A.
    Clark, J. W.
    Tye, L.
    Wilner, Keith
    Stephenson, P.
    Chung, D. H.
    Varella-Garcia, M.
    Iafrate, A. J.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S455 - S455
  • [23] CLINICAL AND PROGNOSTIC IMPLICATION OF ALK AND ROS1 REARRANGEMENT IN NEVER SMOKER WITH SURGICALLY RESECTED LUNG ADENOCARCINOMA
    Kim, Hye Ryun
    Kim, Min Hwan
    Lim, Sun-Min
    Kim, Eun Young
    Park, Ji Soo
    Kim, Joo Hang
    Shim, Hyo Sup
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1220 - S1220
  • [24] A COMPARISON OF FISH AND IMMUNOHISTOCHEMISTRY IN THE DETECTION OF ALK REARRANGEMENT IN LUNG ADENOCARCINOMA
    Le Quesne, John
    Maurya, Manisha
    De Castro, David Gonzalez
    Popat, Sanjay
    Wotherspoon, Andrew
    Nicholson, Andrew
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1085 - S1086
  • [25] Biomarkers that currently affect clinical practice in lung cancer: EGFR ALK, ET, ROS-1, and KRAS
    Korpanty, Grzegorz J.
    Graham, Donna M.
    Vincent, Mark D.
    Leigh, Natasha B.
    FRONTIERS IN ONCOLOGY, 2014, 4 : 1 - 26
  • [26] Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement
    Rafee, Shereen
    Elamin, Yasir Y.
    Joyce, Eimear
    Toner, Mary
    Flavin, Richard
    McDermott, Ronan
    Sheehy, Niall
    Hennessy, Bryan
    O'Byrne, Kenneth
    Gleeson, Noreen
    Osman, Nemer
    TUMORI, 2015, 101 (02) : E35 - E39
  • [27] Complementary Utility of Combined ALK/ROS1 FISH with Immunohistochemistry for ALK/ROS1 Rearrangement Testing in Lung Cancer
    Nambirajan, A.
    Singh, V.
    Rana, D.
    Malik, P.
    Mohan, A.
    Jain, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1160 - S1160
  • [28] Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC
    Gibson, A.
    Dean, M.
    Elegbede, A. J.
    Pabani, A.
    Bebb, G. J.
    Cheung, W. Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S402 - S402
  • [29] Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma
    Zhu, You-cai
    Liao, Xing-hui
    Wang, Wen-xian
    Xu, Chun-wei
    Zhuang, Wu
    Wei, Jian-guo
    Du, Kai-qi
    THORACIC CANCER, 2018, 9 (02) : 324 - 327
  • [30] Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
    Ryu, Woo Kyung
    Cha, Hyungkeun
    Park, Mi Hwa
    Kim, Jung Soo
    Choi, Jeong-Seok
    Kim, Lucia
    Lee, Kyung-Hee
    Nam, Hae-Seong
    FRONTIERS IN ONCOLOGY, 2022, 12
12345